Abstract:Clustered regularly interspaced palindromic repeats (CRISPR) is a gene editing tool with tremendous therapeutic potential. Recently, ribonucleoprotein (RNP) complex‐based CRISPR systems have gained momentum due to their reduction of off‐target editing. This has coincided with the emergence of extracellular vesicles (EVs) as a therapeutic delivery vehicle due to its low immunogenicity and high capacity for manipulation. EVs are cell‐derived membranous nanoparticles which mediate the intercellular transfer of molecular components. Current technologies achieve CRISPR RNP encapsulation into EVs through EVs biogenesis, thereby avoiding unnecessary physical, chemical or biological manipulations to the vesicles directly. Herein, we identify sixteen EVs‐based CRISPR RNP encapsulation strategies, each with distinct genetic features to encapsulate CRISPR RNP. According to the molecular mechanism facilitating the encapsulation process, there are six strategies of encapsulating Cas9 RNP into virus‐like particles based on genetic fusion, seven into EVs based on protein tethering, and three based on sgRNA‐coupled encapsulation. Additionally, the incorporation of a targeting moiety to the EVs membrane surface through EVs biogenesis confers tropism and increases delivery efficiency to specific cell types. The targeting moieties include viral envelope proteins, recombinant proteins containing a ligand peptide, single‐chain fragment variable (scFv) antibodies, and integrins. However, current strategies still have a number of limitations which prevent their use in clinical trials. Among those, the incorporation of viral proteins for encapsulation of Cas9 RNP have raised issues of biocompatibility due to host immune response. Future studies should focus on genetically engineering the EVs without viral proteins, enhancing EVs delivery specificity, and promoting EVs‐based homology directed repair. Nevertheless, the integration of CRISPR RNP encapsulation and tropism technologies will provide strategies for the EVs‐based delivery of CRISPR RNP in gene therapy and disease treatment.

The CRISPR/Cas9 System Delivered by Extracellular Vesicles

CRISPR/Cas9 delivery strategies with engineered extracellular vesicles

Current and prospective strategies for advancing the targeted delivery of CRISPR/Cas system via extracellular vesicles

CRISPR delivery with extracellular vesicles: Promises and challenges

Gene Editing by Extracellular Vesicles

CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles

Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing

Functionalized extracellular nanovesicles as advanced CRISPR delivery systems

Cell-derived extracellular vesicles for CRISPR/Cas9 delivery: engineering strategies for cargo packaging and loading

Exosomes as Targeted Delivery Platform of CRISPR/Cas9 for Therapeutic Genome Editing

Advances in delivery systems for CRISPR/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles

Engineered Cas9 extracellular vesicles as a novel gene editing tool

Delivery of CRISPR/Cas9 for Therapeutic Genome Editing

New Therapeutics for Extracellular Vesicles: Delivering CRISPR for Cancer Treatment

Viral Vectors for the in Vivo Delivery of CRISPR Components: Advances and Challenges

CRISPR/Cas9 Delivery System Engineering for Genome Editing in Therapeutic Applications

Viral vectors and extracellular vesicles: innate delivery systems utilized in CRISPR/Cas-mediated cancer therapy

Non-viral and Viral Delivery Systems for CRISPR-Cas9 Technology in the Biomedical Field

Challenges in Crispr/Cas9 Delivery: Potential Roles of Nonviral Vectors

Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing